Table 1.
Clinical and demographic characteristics of the study cohort.
| MS patients (N = 96) | Healthy Controls (N = 21) | |
|---|---|---|
| Gender, n (%) | ||
| ▒Female | 57 (59.4) | 11 (52.4) |
| ▒Male | 39 (40.6) | 10 (47.6) |
| Age, years | ||
| ▒Mean age (±SD) | 40.7 (±10.5) | 48.3 (±10.8) |
| ▒IQR (25–75) | 14.5 | 20.5 |
| EDSS, mean (range) | 1.9 (0–6.5) | |
| DMTs duration, mean (months ± SD) | 50.2 (±41.5) | |
| MS type, n (%) | ||
| ▒RRMS | 91 (94.8) | |
| ▒PPMS | 1 (1.04) | |
| ▒SPMS | 4 (4.2) | |
| DMTs, n (%) | ||
| ▒Interferon -β 1a | 19 (19.8) | |
| ▒Natalizumab | 14 (14.6) | |
| ▒Dimethyl fumarate | 14 (14.6) | |
| ▒Ocrelizumab | 13 (13.5) | |
| ▒Fingolimod | 13 (13.5) | |
| ▒Teriflunomide | 8 (8.3) | |
| ▒Cladribine | 8 (8.3) | |
| ▒Glatiramer acetate | 7 (7.4) |
DMTs: Disease modifying therapy; EDSS: Expanded disability status scale; IQR: Interquartile range; MS: Multiple sclerosis; PPMS: Primary progressive multiple sclerosis; RRMS: Relapsing remitting multiple sclerosis; SPMS: Secondary progressive multiple sclerosis.